Where quality systems, regulatory affairs, and AI governance converge. Navigate FDA AI/ML frameworks, GxP validation requirements, and the EU AI Act with a consultant who has lived on both sides of the regulatory table.
The Landscape
From clinical decision support and medical imaging to drug discovery and patient monitoring, artificial intelligence is reshaping how healthcare organizations deliver care, develop therapeutics, and manage operations. The FDA has authorized over 950 AI/ML-enabled medical devices. Pharmaceutical companies are using AI to compress drug development timelines from 12 years to potentially 5–7. Hospital systems are deploying AI for everything from sepsis prediction to surgical planning. But the governance frameworks needed to manage these systems responsibly are far behind the technology.
AI systems that assist clinicians with diagnosis, treatment recommendations, and patient risk stratification. Regulatory classification depends on intended use and the degree of clinician oversight.
AI-powered target identification, molecular design, clinical trial optimization, and pharmacovigilance. GxP validation requirements apply when AI impacts product quality or patient safety decisions.
Computer-aided detection and diagnosis in radiology, pathology, dermatology, and ophthalmology. Represents the largest category of FDA-authorized AI/ML devices, with stringent performance validation requirements.
Real-time AI systems for continuous patient monitoring, early warning scores, and deterioration prediction. These systems often operate in high-acuity settings where algorithm failures have immediate patient safety implications.
AI in pharmaceutical manufacturing for process analytical technology, predictive maintenance, batch release, and quality control. Subject to GMP requirements and 21 CFR Part 11 data integrity standards.
AI for prior authorization, claims processing, coding assistance, and resource scheduling. While lower-risk than clinical AI, these systems still face HIPAA, bias, and transparency requirements that demand governance oversight.
Regulatory Framework
The FDA has been actively developing a regulatory framework for AI and machine learning in medical products since 2019. Understanding these evolving requirements is essential for any organization developing or deploying AI in healthcare. Here are the key components every healthcare AI program must address.
The PCCP is the FDA's answer to the fundamental challenge of regulating adaptive AI/ML algorithms. Traditional device regulation assumes a "locked" product at the time of authorization, but AI systems are designed to evolve. The PCCP allows manufacturers to describe planned modifications, retraining protocols, and performance safeguards in advance — enabling post-market algorithm updates without requiring a new submission for each change.
Key deliverable: A PCCP that defines the scope of anticipated changes, the methodology for implementing and validating changes, and the performance boundaries that trigger a new regulatory submission.
Developed jointly by the FDA, Health Canada, and the UK MHRA, the GMLP guiding principles establish expectations for AI/ML-enabled medical device development. They address data management, model training and evaluation, clinical validation, and real-world performance monitoring. GMLP aligns with traditional GxP concepts but adapts them to the unique characteristics of machine learning systems.
Key deliverable: A GMLP-aligned development and validation framework that your teams can follow from data collection through post-market monitoring.
The SaMD framework classifies AI software based on the significance of the information it provides and the healthcare situation or condition it addresses. The International Medical Device Regulators Forum (IMDRF) framework categorizes SaMD into risk levels that determine the regulatory pathway: 510(k), De Novo classification, or Premarket Approval (PMA). Understanding which pathway applies to your AI system is the first step in regulatory strategy.
Key deliverable: Risk classification and regulatory pathway determination for each AI system in your portfolio.
The FDA's TPLC approach to AI/ML-enabled devices emphasizes continuous monitoring and improvement throughout the product lifecycle — not just at the point of market authorization. This includes real-world performance monitoring, post-market surveillance, adverse event reporting, and ongoing validation that the AI system continues to perform as intended across diverse patient populations and clinical settings.
Key deliverable: Post-market monitoring plan with defined performance metrics, drift detection mechanisms, and escalation procedures.
Governance Challenges
Healthcare AI governance is uniquely complex because it sits at the intersection of patient safety, clinical efficacy, regulatory compliance, and data privacy. Each of these challenges requires specialized expertise to navigate effectively.
Exempt vs. Non-Exempt CDS
The 21st Century Cures Act exempts certain clinical decision support (CDS) software from FDA regulation — but the exemption criteria are narrower than many organizations realize. To be exempt, CDS must meet all four criteria: (1) not intended to acquire, process, or analyze a medical image, signal, or pattern, (2) intended for displaying, analyzing, or printing medical information about a patient or other medical information, (3) intended for use by a healthcare professional, and (4) intended to enable the professional to independently review the basis for the recommendation.
The fourth criterion — transparency of the recommendation basis — is where most AI systems fail the exemption test. If the AI system cannot explain its reasoning in a way that allows the clinician to independently evaluate the recommendation, it is not exempt CDS and requires FDA regulatory oversight. This determination has significant implications for your regulatory strategy, development timeline, and governance requirements.
GxP Validation Requirements
AI systems used in pharmaceutical development face GxP validation requirements when they impact product quality, safety, or efficacy decisions. This includes AI used for target identification, molecular design, ADMET prediction, clinical trial design, biomarker analysis, and pharmacovigilance. The validation approach must address the unique characteristics of ML models: non-deterministic outputs, sensitivity to training data, and the potential for concept drift over time.
Traditional computer system validation (CSV) methodologies were designed for deterministic software. AI/ML systems require adapted approaches that account for probabilistic outputs, training data management, model lifecycle governance, and performance monitoring. Organizations need validation frameworks that satisfy GxP requirements while remaining practical for the iterative, data-driven nature of AI development.
Health Equity Implications
Algorithmic bias in clinical AI systems can perpetuate or amplify health disparities across racial, ethnic, gender, and socioeconomic lines. The most well-known example — the Optum algorithm that systematically deprioritized Black patients for care management programs — demonstrated how proxy variables in training data can encode structural racism into clinical workflows. But bias risks extend far beyond this single case.
Medical imaging AI trained predominantly on data from lighter-skinned populations may perform less accurately on darker-skinned patients. Risk prediction models trained on utilization data may underestimate disease burden in populations with less access to healthcare. Clinical trial AI may inadvertently exclude patient subgroups from analysis. Effective AI governance must include systematic bias testing across demographic subgroups, ongoing performance monitoring, and clear processes for addressing disparities when they are detected.
Privacy in the AI Pipeline
AI systems in healthcare consume, process, and generate protected health information (PHI) at every stage of the pipeline — from training data to inference outputs. HIPAA's Privacy and Security Rules apply to AI systems that handle PHI, but the rules were written before modern AI architectures existed. Organizations must address questions that HIPAA alone doesn't fully answer: How do you de-identify training data in a way that preserves clinical utility while protecting privacy? What are the minimum necessary data requirements for model training? How do you manage re-identification risk when combining multiple data sources?
AI governance programs must address data governance across the full AI lifecycle: data acquisition and consent, de-identification and anonymization, secure training environments, model output handling, and third-party data sharing. This requires coordination between privacy officers, IT security, data engineers, and AI development teams.
Supply Chain Governance
Healthcare organizations increasingly deploy AI systems they did not build — purchased from vendors, embedded in EHR platforms, or integrated through third-party APIs. The governance challenge is significant: your organization bears responsibility for the AI's clinical impact regardless of who developed it. Vendor due diligence must assess model validation methodology, training data characteristics, bias testing results, performance monitoring capabilities, and the vendor's own governance practices. Many healthcare AI vendors cannot yet provide this information in a structured format, which itself is a risk signal that governance programs must address.
Our Services
Every engagement is tailored to your organization's specific AI portfolio, regulatory exposure, and governance maturity. Here are the core service areas we deliver for healthcare, pharma, and medical device clients.
Risk-based validation frameworks for AI/ML systems used in GxP-regulated processes. Adapted from GAMP 5 and ISPE guidelines to address the unique characteristics of machine learning models, including probabilistic outputs, training data management, and model lifecycle governance.
Regulatory strategy and documentation support for AI/ML-enabled medical devices. Includes SaMD classification, regulatory pathway determination, PCCP development, clinical validation planning, and pre-submission meeting preparation with the FDA.
Governance frameworks for clinical decision support systems, including exempt/non-exempt classification, clinical validation requirements, clinician training programs, ongoing monitoring, and bias testing across patient subgroups.
AI risk management frameworks tailored for pharmaceutical development. Covers GxP validation for AI in drug discovery, clinical trial optimization, manufacturing process control, pharmacovigilance, and regulatory submission support.
Integrated compliance programs for medical AI that must satisfy both the EU AI Act and the Medical Device Regulation. Addresses the additive requirements, dual conformity assessment process, and documentation demands of operating under both frameworks simultaneously.
Systematic bias testing and health equity assessment for clinical AI systems. Evaluates model performance across demographic subgroups, identifies disparity risks, and establishes ongoing monitoring to detect and address emerging bias in production AI systems.
The Differentiator
Healthcare AI governance sits at a unique intersection: quality systems, regulatory affairs, legal compliance, and artificial intelligence. Most AI governance consultants understand AI but not GxP. Most quality consultants understand GxP but not AI. Most regulatory affairs professionals understand FDA submissions but not AI risk management. Most lawyers understand compliance but not quality systems.
Jared Clark holds the rare combination of credentials that maps directly to this intersection: a Juris Doctor for legal and regulatory analysis, a Certified Manager of Quality/Organizational Excellence (CMQ-OE) for quality systems expertise, and a Regulatory Affairs Certification (RAC) for FDA and EU regulatory knowledge. Add project management (PMP) and business strategy (MBA), and you have the exact skill stack healthcare AI governance requires.
This isn't a consulting team where different people bring different pieces. This is one senior practitioner who bridges all the disciplines — someone who can speak the language of your quality team, your regulatory affairs department, your legal counsel, and your AI engineers in a single meeting.
ASQ-certified quality management expertise. AI governance is fundamentally a quality management challenge — the CMQ-OE credential provides the methodology to build management systems that actually work.
RAPS-certified regulatory affairs spanning FDA, EU MDR, and EU AI Act. Knows how regulators evaluate AI systems because he's worked on the regulatory side of the table.
Legal training for regulatory interpretation, compliance analysis, and contract structures. Essential for navigating the overlapping legal requirements of FDA, HIPAA, EU AI Act, and MDR.
PMI-certified project management ensures governance implementations deliver on time and within scope — not open-ended consulting engagements that drift without clear milestones.
FAQ
Start with a free 30-minute consultation focused on your specific healthcare AI governance challenges. We'll discuss your AI portfolio, regulatory exposure, and what a governance program looks like for your organization. No generic frameworks — just practical guidance grounded in quality systems, regulatory affairs, and AI expertise.
Or email support@certify.consulting